Clinical Trials Logo

Refractory AL Amyloidosis clinical trials

View clinical trials related to Refractory AL Amyloidosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04270175 Recruiting - AL Amyloidosis Clinical Trials

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.